01 Growing Demand for Aquatic Animal-Derived Food ProductsFarmers are encouraged to utilize vaccinations for aquaculture to increase the profitability of the rising demand for food products made from aquatic animals, such as oil, caviar, protein powders, and meat. Consumers are becoming more aware of the nutritive benefits of animal protein as a result of the increase in urbanization. In addition, the demand for beef products that are healthful, sustainable, high-quality, and contain little to no medications is also rising quickly. Aquatic animals now require more care during breeding, which is expected to increase demand for aquaculture vaccines and expand the market.Consumers are also becoming aware of the importance of micronutrients, the natural sources of which are fish-based proteins. These micronutrients include vitamin D. Another micronutrient is vitamin B12, the only natural source of animal proteins, such as tuna. As a result, the market for aquaculture vaccines is expanding due to the increasing demand for these micronutrients and the consequent increase in demand for fish meat. The high value of aquatic animal-derived food products is expected to increase the demand for aquaculture vaccines for delivering healthy fish meat.
02 High Prevalence of Infectious Diseases in the Aquaculture SectorThe prevalence of infectious diseases in aquatic animals is increasing owing to adverse climatic transformations and rapid globalization. Government initiatives mandating safe healthcare practices for aquaculture production are expected to grow the aquaculture vaccine market. Several governments worldwide are focused on protecting these animals from diseases. In addition, efforts are being undertaken to increase awareness about these diseases and their diagnosis and treatment through fish farmers.According to the Aquaculture Research & Development journal, from 2014 to 2018, approximately 219 infectious diseases in the fresh aquaculture sector were registered. Some 74.88% were caused by parasites, 12.80% by bacteria, 1.83% by viruses, and 10.50% by a combination of parasitic and bacterial diseases. Therefore, such a high prevalence of infectious diseases is expected to boost the demand for vaccines, fueling the market growth.
01 Slowdown of Global Aquaculture GrowthAccording to the Fish Site, global aquaculture's growth rate decreased from 10% annually to 2% in 2018. It also stated that the total aquaculture harvest in 2018 reached an all-time high of approximately 114.5 million tons. Although the aquaculture production quantity is high, the industry's growth rate has slowed down. Significant aquaculture market production, i.e., the European countries, must grow.Additionally, the growth of the aquaculture industry requires political support for promoting appropriate policies, strategies, and public and private investment. According to the European aquaculture producers, the biggest challenge for the continued advancement of the aquaculture segment is the acceptance of appropriate general governance verdicts aiming precisely to promote aquaculture development amidst all the other economic activities.
01 Development of Novel VaccinesThe genomes of a variety of fish species are now available. As the price of technology like whole genome sequencing continues to drop, more and more reports of these viruses' genomes are being published, paving the way for species-specific vaccine development. These factors provide lucrative opportunities for market players to invest in developing new vaccines against bacterial, viral, or parasitic infectious diseases for which vaccines are currently unavailable. Moreover, developing effective mucosal vaccines and optimizing their delivery is expected to expedite novel vaccine development and enable aquaculture businesses in low- and middle-income countries to use vaccination habitually. Furthermore, the effective use of emergency (autogenous) vaccines is expected to help address emerging disease challenges and create tremendous opportunities for the market players to grow.
June 2026 Vaxxinova obtained regulatory approval in Norway for Vaxxon® Yersinia vet, strengthening its presence in the European aquaculture vaccines market with a new injectable vaccine for salmonid disease prevention.
May 2026 HIPRA launched ICTHIOVAC® VR/PD in Turkey, expanding the availability of its injectable vaccine for sea bass against vibriosis and pasteurellosis to support disease prevention in Mediterranean aquaculture.
June 2025 BioMar Group and Agronutris entered a strategic collaboration to accelerate the development and commercialization of insect-based feed ingredients for aquaculture, supporting sustainable fish production and improving overall aquatic animal health.